Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check50 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check64 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check71 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.SummaryDifference1.0%
- Check100 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.